Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis

BACKGROUND/OBJECTIVE: The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. METHODS: Data from SPIRIT-P1 and SPIRIT-P2 were analysed to eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, Laura C, Smolen, Josef S, Mease, Philip J, Husni, M. Elaine, Merola, Joseph F., Lespessailles, Eric, Kishimoto, Mitsumasa, Macpherson, Lisa, Bradley, Andrew J, Bolce, Rebecca, Helliwell, Philip S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528721/
https://www.ncbi.nlm.nih.gov/pubmed/36171019
http://dx.doi.org/10.1136/rmdopen-2022-002457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528721/
https://www.ncbi.nlm.nih.gov/pubmed/36171019
http://dx.doi.org/10.1136/rmdopen-2022-002457

Ejemplares similares